Targeting cancer stem cells and signalling pathways through phytochemicals: A promising approach against colorectal cancer

Liao, Wenhao; Zhang, Lanlan; Chen, Xian; Xiang, Juyi; Zheng, Qiao; Chen, Nianzhi; Zhao, Maoyuan; Zhang, Gang; Xiao, Xiaolin; Zhou, Gang; Zeng, Jinhao; Tang, Jianyuan

doi:10.1016/j.phymed.2022.154524

Cited by 31 publications

(19 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, CSCs are present in CRC tissues. CSCs are cancer cells with stem cell properties such as self-replication and multicellular differentiation, which are responsible for CRC recurrence and metastasis [ 56 , 57 ]. During CRC metastasis, a few surviving CTC subpopulations have the CSCs phenotype [ 58 ].…”

Section: Mechanisms Underlying the Promotion Of Crc Metastasis By Imb...mentioning

confidence: 99%

Role of imbalanced gut microbiota in promoting CRC metastasis: from theory to clinical application

Fan,

Zhou,

Zhang

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Metastasis poses a major challenge in colorectal cancer (CRC) treatment and remains a primary cause of mortality among patients with CRC. Recent investigations have elucidated the involvement of disrupted gut microbiota homeostasis in various facets of CRC metastasis, exerting a pivotal influence in shaping the metastatic microenvironment, triggering epithelial-mesenchymal transition (EMT), and so on. Moreover, therapeutic interventions targeting the gut microbiota demonstrate promise in enhancing the efficacy of conventional treatments for metastatic CRC (mCRC), presenting novel avenues for mCRC clinical management. Grounded in the “seed and soil” hypothesis, this review consolidates insights into the mechanisms by which imbalanced gut microbiota promotes mCRC and highlights recent strides in leveraging gut microbiota modulation for the clinical prevention and treatment of mCRC. Emphasis is placed on the considerable potential of manipulating gut microbiota within clinical settings for managing mCRC.

show abstract

Section: Mechanisms Underlying the Promotion Of Crc Metastasis By Imb...mentioning

confidence: 99%

Role of imbalanced gut microbiota in promoting CRC metastasis: from theory to clinical application

Fan,

Zhou,

Zhang

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…Plants have been an important source for drug development and translational medicine since ancient times due to their abundance, high safety profile, and multiple mechanisms of action. 37 However, the clinical applicability of phytochemicals is often hampered by their low bioavailability, which may be associated with their low solubility and/or susceptibility to degradation in aqueous media. For example, the bioavailability of quercetin in humans after oral administration was as low as 1%, which was attributed to poor aqueous solubility (2.84 mg/mL).…”

Section: Natural Product Components In Inhaled Formulationsmentioning

confidence: 99%

Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases

Yong,

Shu,

Zhang

et al. 2024

IJN

View full text Add to dashboard Cite

Given the unique physiological and pathological characteristics of the lung, the direct, inhalable route is more conducive to pulmonary drug delivery and disease control than traditional systemic drug delivery, significantly circumventing drug loss, off-target effects, systemic and organ toxicity, etc., and is widely regarded as the preferred regimen for pulmonary drug delivery. However, very few lung diseases are currently treated with the preferred inhaled formulations, such as asthma, chronic obstructive pulmonary disease and pulmonary hypertension. And there is a lack of appropriate inhaled formulations for other critical lung diseases, such as lung cancer and pulmonary fibrosis, due to the fact that the physicochemical properties of the drugs and their pharmacokinetic profiles do not match the physiology of the lung, and conventional inhalation devices are unable to deliver them to the specific parts of the lung. Phytochemicals of natural origin, due to their wide availability and clear safety profile, hold great promise for the preparation of inhalable formulations to improve the current dilemma in the treatment of lung diseases. In particular, the preparation of inhalable formulations based on nano- and microparticulate carriers for drug delivery to deep lung tissues, which overcome the shortcomings of conventional inhalation therapies while targeting the drug activity directly to a specific part of the lung, may be the best approach to change the current dilemma of lung disease treatment. In this review, we discuss recent advances in nano- and micron-carrier-based inhalation formulations for the delivery of natural products for the treatment of pulmonary diseases, which may represent an opportunity for practical clinical translation of natural products.

show abstract

“…Taken into account of the reports about the LVN resistance, strategies on blockage or knockout, knochdwon the targets supplied the simplest way to conquer resistance. In HCC, CSCs plays the role not only initiating tumor development, inducing tumor progression but also modulating chemotherapy resistance ( Fang et al, 2022 ; Mayani et al, 2022 ; Liao et al, 2023 ). Herein, the aim of targeting therapy to eradicate CSCs displays the potential to hinder HCC progression.…”

Section: Potential Ways To Conquer Lvn’s Resistancementioning

confidence: 99%